The market value for therapies used in the treatment of hematological cancers has increased substantially in the past 10 years. The total sales for marketed therapeutics for hematological cancers were valued at $58 billion in 2020. The total sales include the sales of branded and biosimilar marketed agents, but not generics.
The hematological cancer therapy market is diverse and highly genericized. There are 2,406 marketed molecules for the treatment of hematological cancers available globally. The majority of these are generic chemotherapies. There are 248 branded molecules available globally, of which chemotherapies are the largest group. The market also consists of a wide range of molecularly targeted therapies and antibodies and is pioneering the use of cell therapies for the treatment of cancer.
Overview of global hematological cancer therapy market
For more insights on this report, download a free report sample
What are the key treatments of hematological cancers?
GlobalData has classified the treatments of hematological cancers into five groups:
- Antibodies: Antibodies are used to target specific proteins on cancer cells with the aim of inducing cell death. Sales of antibody products are expected to increase by 2027 at an estimated CAGR of more than 10%.
- Cell therapies: Cellular therapies include adoptive and cytotoxic cell therapies, including chimeric antigen receptor (CAR) T cells. Sales of cell therapy products are expected to see the largest increase in sales, with an estimated CAGR of more than 20% by 2027.
- Chemotherapies: Chemotherapy drugs kill non-specifically, growing cells in the body. Chemotherapies form the backbone of treatment of numerous hematological cancers and may be used alone, or in combination with therapies with different mechanisms of action (MOA). Sales of chemotherapies are expected to increase modestly until 2026 and then fall, with a CAGR of more than 5%.
- Other therapies: Drugs with distinct MOAs that are used in the treatment of hematological cancers include recombinant enzymes and steroids for Hodgkin’s lymphoma and NHLs. Sales of products with other mechanisms of action are expected to increase substantially by 2027, with a CAGR of more than 15%.
- Targeted therapies: Small molecule targeted therapies aim to bind to and inhibit or antagonize the function of a specific protein. Sales of targeted therapies are expected to increase modestly at a CAGR of more than 3%.
Targeted therapies accounted for the highest proportion of sales in 2020 followed by antibodies. Since 2017 the sales of cell therapies have seen a sharp increase.
Global hematological cancer therapy market, by treatments
For more insights on this report, download a free report sample
What are the market dynamics of the global hematological cancer therapy market?
Significant unmet needs are expected to remain in the market, which presents considerable commercial opportunities. Particularly, the lack of options for relapsed/refractory and some high-risk patients is an issue. The increasingly high costs of therapy are set to put pressure on healthcare systems so novel therapies that can be offered at lower costs are particularly needed. The hematological cancer pipeline is dominated by cell therapies, small molecules, and antibodies, but also features a range of novel therapeutic approaches including vaccines, gene therapies, and peptides. A wide variety of novel and tried-and-tested targets are also being investigated.
The use of cellular therapies, particularly CAR-T, has grown dramatically in recent years. These personalized treatments are now available for patients with NHLs (including follicular lymphoma, DLBCL, and MCL), ALL, and multiple myeloma, and appear to induce durable responses in a high proportion of patients.
Cell therapies are also the most actively investigated molecule type within the hematological cancer pipeline. Chemotherapy still forms the backbone of treatment for numerous hematological cancers, and the presence of multiple generic versions can keep costs relatively low in some cases. However, chemotherapy is increasingly being used in combination with targeted therapies or being pushed back to later lines in some indications, which will also drive up the costs to healthcare systems.
What are the opportunities and challenges of the global hematological cancer therapy market?
No allogeneic cell therapies have been approved in any indications. The off-the-shelf nature of such products could see them used in patients who are ineligible for autologous cell therapies due to rapidly progressing disease, or those for whom CAR-T cells cannot be manufactured. These could also be used as a bridging therapy to stem cell transplant or CAR-T and therefore offer great potential.
Bispecific antibodies also represent a major opportunity. There is currently only one bispecific antibody approved for the treatment of hematological cancers and there is considerable enthusiasm surrounding this approach. As a greater understanding of the molecular basis of disease is gained, there is the potential for developers to repurpose existing drugs in novel combinations in order to target specific pathways or proteins that are dysregulated in hematological cancers.
As focus on cell therapies continues, a major challenge lies in making these therapies available to wider patient populations. Limited uptake can be explained by two major factors: the very high cost of therapy and the complex logistics associated with administering treatment necessitating use of highly specialized centers to deliver care. There are also disparities between markets in terms of access to newer therapies, particularly CAR-T, and in some cases, there may also be reimbursement barriers once an agent is approved.
Which are the major companies in global hematological cancer therapy market?
In global hematological cancer therapy market, the major companies include AbbVie, Amgen, BMS, InCyte Corp, Johnson & Johnson/Janssen, Novartis, Pfizer, Takeda, and Roche.
Global hematological cancer therapy market, by key players
To know more about key players, download a free report sample
Market report scope
|Market size (Year – 2020)||$58 billion|
|Base year for estimation||2020|
|Key Treatments||Antibodies, Cell therapies, Chemotherapies, Other therapies, Targeted therapies|
|Key players||AbbVie, Amgen, BMS, InCyte Corp, Johnson & Johnson/Janssen, Novartis, Pfizer, Takeda and Roche|
This report provides a comprehensive analysis of the global hematological cancer therapy market. It provides:
- Overview of hematological cancers including classification and treatment management, and important milestones in the treatment of hematological cancers in the 8MM.
- Global trends in the hematological cancer market, including the impact of cell therapies on the market and how their use is expected to evolve, and how the increased understanding of the molecular basis of the disease is influencing treatment, diagnosis, and prognosis across different hematological cancer indications.
- Key topics covered include ongoing clinical trials, top-selling agents from each treatment type, pipeline therapies, market analysis by treatment type, an overview of noteworthy deals, and unmet needs and opportunities.
- Pipeline analysis: Overview of pipeline products globally and in the 8MM, including a breakdown by treatment type and split across different phases, analysis of highly investigated targets, an overview of pipeline products by indication, phase, and treatment type.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global hematological cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hematological cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the global hematological cancer therapeutics market from 2020-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bristol Myers Squibb
CSPC Pharmaceutical Group
Johnson & Johnson/Janssen
Table of Contents
Table of Contents (PowerPoint Deck)
1.1. Table of Contents
1.3. Related Reports
2. Executive Summary
2.1. Key Findings
3. Hematological Cancer Overview
3.1. What Are Hematological Cancers?
3.2. Treatment Management for Hematological Cancers
3.3. Important Milestones in the Treatment of Hematological Cancers in the 8MM
4.1. Industry Trends
5. Value Chain
5.1. Hematological Cancers Value Chain
5.3. Cell Therapies
5.5. Other MOAs
5.6. Targeted Therapies
6. Clinical Trials
6.1. Clinical Trials for Hematological Cancers
6.2. Ongoing Clinical Trials for Hematological Cancers
6.3. Ongoing Clinical Trials for Hematological Cancers by Region
6.4. Ongoing Clinical Trials in Hematological Cancers by Leading Sponsors
6.5. Clinical Trials in Hematological Cancers – Challenges
6.6. Clinical Trials in Hematological Cancers – Opportunities
7. Marketed Products
7.1. Hematological Cancers Marketed Products Globally
7.2. Hematological Cancers Marketed Products in the 8MM
7.3. Total Market Size for Hematological Cancers
7.4. Leading Antibody Treatments Globally
7.5. Leading Cell Therapy Treatments Globally
7.6. Leading Chemotherapy Treatments Globally
7.7. Leading Treatments with Other MOAs Globally
7.8. Leading Targeted Therapy Treatments Globally
8. Pipeline Products
8.1. Global Hematological Cancer Pipeline Products
8.2. Global Hematological Cancer Pipeline – Antibodies
8.3. Global Hematological Cancer Pipeline – Cell Therapies
8.4. Global Hematological Cancer Pipeline – Chemotherapies
8.5. Global Hematological Cancer Pipeline – Other MOAs
8.6. Global Hematological Cancer Pipeline – Targeted Therapies
9. Market Analysis
9.1. Market Analysis and Forecast – Antibodies
9.2. Market Analysis and Forecast – Cell Therapies
9.3. Market Analysis and Forecast – Chemotherapies
9.4. Market Analysis and Forecast – Other MOAs
9.5. Market Analysis and Forecast – Targeted Therapies
9.6. Top 10 Completed Deals in the Hematological Cancer Space Since 2017
9.7. Latest Deals in the Hematological Cancer Space
9.8. Mergers and Acquisitions Hematological Cancer – H2 2020–H1 2021
9.9. Mergers and Acquisitions Hematological Cancer – H2 2020
10.2. Johnson & Johnson/Janssen
11. Opportunities and Unmet Needs
11.1. Global Hematological Cancers – Opportunities
11.2. Global Hematological Cancers – Challenges
11.3. Unmet Needs in Hematological Cancers – Gap Analysis
12.2. Primary Research
12.3. About the Authors
12.4. About GlobalData
12.5. Contact Us
Frequently Asked Questions
The total global hematological cancer therapy market value was $58 billion in 2020.
The key treatments of hematological cancers are antibodies, cell therapies, chemotherapies, other therapies, and targeted therapies.
In the global hematological cancer therapy market, the major companies include AbbVie, Amgen, BMS, InCyte Corp, Johnson & Johnson/Janssen, Novartis, Pfizer, Takeda, and Roche.